Search Results - Peter Borchmann

Refine Results
  1. 1

    Lymphoma immunotherapy: Efficacy, safety and accessibility to CAR-T therapy for lymphomas by Peter Borchmann

    Published in HemaSphere (2018-06-01)
    Get full text
    Article


  2. 2

    P078: Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors by Nele Stadtbaeumer, Axel Mayer, Peter Borchmann

    Published in HemaSphere (2022-10-01)
    Get full text
    Article


  3. 3

    Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia by Thomas Elter, Julia Kilp, Peter Borchmann, Holger Schulz, Michael Hallek, Andreas Engert

    Published in Haematologica (2009-01-01)
    Get full text
    Article


  4. 4

    Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis by Peter Borchmann, Jan-Michel Heger, Jörg Mahlich, Michael S. Papadimitrious, Sybille Riou, Barbara Werner

    Published in Oncology and Therapy (2022-11-01)
    Get full text
    Article


  5. 5

    Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin’s lymphoma: results of a prematurely closed phase II study (NCT00148018) by Sven Trelle, Orhan Sezer, Ralph Naumann, Mathias Rummel, Ulrich Keller, Andreas Engert, Peter Borchmann

    Published in Haematologica (2007-04-01)
    Get full text
    Article


  6. 6

    P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial by Paul J. Bröckelmann, Helen Kaul, Michael Fuchs, Carsten Kobe, Christian Baues, Peter Borchmann, Andreas Engert

    Published in HemaSphere (2022-10-01)
    Get full text
    Article


  7. 7

    Survival outcomes of patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation in Germany: real-world evidence from an administrative database bet... by Jan-Michel Heger, Peter Borchmann, Sybille Riou, Barbara Werner, Michael S. Papadimitrious, Jörg Mahlich, Jörg Mahlich

    Published in Frontiers in Oncology (2024-10-01)
    Get full text
    Article


  8. 8

    Long non-coding RNA LINC00926 is a biomarker for naïve B-cells with prognostic value in advanced stage classic Hodgkin Lymphoma by Ingram Iaccarino, Thomas Beder, Sarah Reinke, Peter Borchmann, Bastian von Tresckow, Michael Altenbuchinger, Wolfram Klapper

    Published in Haematologica (2025-07-01)
    Get full text
    Article


  9. 9

    The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered by Peter Borchmann, Alexander Fosså, Monika Długosz-Danecka, Boris Böll, Markus Dietlein, Carsten Kobe, Helen Goergen, Andreas Engert

    Published in HemaSphere (2018-06-01)
    Get full text
    Article


  10. 10

    Sustained Remission of Relapsed Diffuse Large B-cell Lymphoma After Safe Administration of CD19-directed CAR T-cells in a Patient With Chronic Intestinal and Pulmonal GvHD by Nadine Kutsch, Philipp Gödel, Conrad-Amadeus Voltin, Carsten Kobe, Michael Hallek, Christof Scheid, Peter Borchmann, Udo Holtick

    Published in HemaSphere (2022-07-01)
    Get full text
    Article


  11. 11

    P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma by Johanna Grund, Sarah Reinke, Annette Plütschow, Bastian Von Tresckow, Peter Borchmann, Andreas Engert, Paul J. Bröckelmann, Wolfram Klapper

    Published in HemaSphere (2022-10-01)
    Get full text
    Article


  12. 12

    Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma by Julia K. Schleifenbaum, Jan-Michel Heger, Jonas Jost, Umberto Rosato, Sybille Riou, Peter Borchmann, Stefan Walzer, Jörg Mahlich

    Get full text
    Article


  13. 13

    Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatmen... by Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, Sven Borchmann, Ilske Oschlies, Antje Schnitter, Andreas Engert, Peter Borchmann, Wolfram Klapper

    Published in Haematologica (2019-01-01)
    Get full text
    Article


  14. 14

    Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment by Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, Ilske Oschlies, Antje Schnitter, Sven Borchmann, Andreas Engert, Peter Borchmann, Wolfram Klapper

    Published in Haematologica (2019-01-01)
    Get full text
    Article


  15. 15

    Hematologic Rescue of CAR T-cell–mediated Prolonged Pancytopenia Using Autologous Peripheral Blood Hematopoietic Stem Cells in a Lymphoma Patient by Philipp Gödel, Noëlle Sieg, Jan-Michel Heger, Nadine Kutsch, Carmen Herling, Ben-Niklas Bärmann, Christof Scheid, Peter Borchmann, Udo Holtick

    Published in HemaSphere (2021-03-01)
    Get full text
    Article


  16. 16

    Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma by Julia Wendler, Richard I. Lewis, Alexandra Kutilina, Markus Knott, Lisa Kristina Isbell, Elke Valk, Peter Borchmann, Jan-Michel Heger, Gerald Illerhaus, Elisabeth Schorb

    Published in Haematologica (2025-01-01)
    Get full text
    Article


  17. 17

    T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies by Dennis A. Eichenauer, Ina Bühnen, Michael Fuchs, Richard Greil, Alden Moccia, Josée. M. Zijlstra, Sylvia Hartmann, Carsten Kobe, Markus Dietlein, Andreas Engert, Peter Borchmann

    Published in HemaSphere (2022-10-01)
    Get full text
    Article


  18. 18

    P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial by Lutz Van Heek, Colin Stuka, Helen Kaul, Horst Müller, Jasmin Mettler, Felicitas Hitz, Christian Baues, Michael Fuchs, Peter Borchmann, Andreas Engert, Markus Dietlein, Conrad-Amadeus Voltin, Carsten Kobe

    Published in HemaSphere (2022-10-01)
    Get full text
    Article


  19. 19

    P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma by Conrad-Amadeus Voltin, Stefanie Kreissl, Helen Kaul, Ina Bühnen, Jasmin Mettler, Thomas Pabst, Dennis A. Eichenauer, Michael Fuchs, Volker Diehl, Markus Dietlein, Andreas Engert, Peter Borchmann, Carsten Kobe

    Published in HemaSphere (2022-10-01)
    Get full text
    Article


  20. 20

    S218: CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHS... by Paul Bröckelmann, Horst Müller, Sarah Gillessen, Anne Sophie Jacob, Jesko Momotow, Carla Damaschin, Justin Ferdinandus, Xiaoqin Yang, Michael Fuchs, Carsten Kobe, Hans T. Eich, Andreas Engert, Peter Borchmann, Bastian von Tresckow

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


Search Tools: